UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Annals of the rheumatic diseases, 2016-02, Vol.75 (2), p.332-340

2016

Volltextzugriff (PDF)

Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus

Annals of the rheumatic diseases, 2009-06, Vol.68 (6), p.828-835

2009

Volltextzugriff (PDF)

THU0635 Pregnancy outcomes in mixed connective tissue disease: results from a multicentre cohort study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.513

2018

Volltextzugriff (PDF)

THU0317 Tubuloinsterstial Damage Is An Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild To Moderate Renal Impairment

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.302-302

2016

Volltextzugriff (PDF)

SAT0016 Correlation of Carotid Intimal Plaque in SLE with Non-Traditional Serum Biomarkers

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.595-595

2014

Volltextzugriff (PDF)

THU0304 Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.297-297

2016

Volltextzugriff (PDF)

SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.538-538

2013

Volltextzugriff (PDF)

SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials’ combined placebo groups

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.540-541

2013

Volltextzugriff (PDF)

SAT0195 Impact of mycophenolate mofetil and/or corticosteroid treatment on outcomes of belimumab treatment in SLE

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.537-538

2013

Volltextzugriff (PDF)

THU0271 Favorable Clinical Response to Belimumab at Three Months

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A257-A257

2013

Volltextzugriff (PDF)

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

Annals of the rheumatic diseases, 2010-10, Vol.69 (10), p.1827-1830

2010

Volltextzugriff (PDF)

AB0615 Favorable response to belimumab seen at three months

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.673-673

2013

Volltextzugriff (PDF)

What’s in a name?

Annals of the rheumatic diseases, 2008-05, Vol.67 (5), p.732

2008

Volltextzugriff (PDF)

What’s in a name?

Annals of the rheumatic diseases, 2008-05, Vol.67 (5), p.732

2008

Volltextzugriff (PDF)

What's in a name?

Annals of the rheumatic diseases, 2008-05, Vol.67 (5), p.732

2008

Volltextzugriff (PDF)

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort

Annals of the rheumatic diseases, 2019-07, Vol.78 (7), p.1010-1012

2019

Volltextzugriff (PDF)

What's in a name?

Annals of the rheumatic diseases, 2007-08, Vol.67 (5), p.732-732

2007

Volltextzugriff (PDF)

BASELINE LABORATORY CHARACTERISTICS FROM THE COMBINED PLACEBO GROUPS IN THE BLISS TRIALS ARE PREDICTIVE OF SEVERE FLARE AT 24 WEEKS

ANNALS OF THE RHEUMATIC DISEASES, 2013, Vol.71, p.538

2013

Volltextzugriff (PDF)

PREDICTORS FOR SLE FLARES: BASELINE DISEASE ACTIVITY AND DEMOGRAPHIC CHARACTERISTICS FROM THE BLISS TRIALS' COMBINED PLACEBO GROUPS

ANNALS OF THE RHEUMATIC DISEASES, 2013, Vol.71, p.540

2013

Volltextzugriff (PDF)

What's in a name?

Annals of the rheumatic diseases, 2008-05, Vol.67 (5), p.732; discussion 732

2008

Volltextzugriff (PDF)

What's in a name?

Annals of the rheumatic diseases, 2008-05, Vol.67 (5), p.732; discussion 732-732; discussion 732

2008

Volltextzugriff (PDF)

FAVORABLE CLINICAL RESPONSE TO BELIMUMAB AT THREE MONTHS

ANNALS OF THE RHEUMATIC DISEASES, 2013, Vol.72, p.257

2013

Volltextzugriff (PDF)

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal

Annals of the rheumatic diseases, 2019-07, Vol.78 (7), p.947-956

2019

Volltextzugriff (PDF)

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Annals of the rheumatic diseases, 2022-08, Vol.81 (8), p.1143-1150

2022

Volltextzugriff (PDF)

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares

Annals of the rheumatic diseases, 2023-10, Vol.82 (10), p.1315-1327

2023

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

KollektionBMJ Journals Archiv - DFG Nationallizenzen

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(24)
Tagungsberichte
(3)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Annals Of The Rheumatic Diseases
(24)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus

THU0635 Pregnancy outcomes in mixed connective tissue disease: results from a multicentre cohort study

THU0317 Tubuloinsterstial Damage Is An Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild To Moderate Renal Impairment

SAT0016 Correlation of Carotid Intimal Plaque in SLE with Non-Traditional Serum Biomarkers

THU0304 Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare

SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks

SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials’ combined placebo groups

SAT0195 Impact of mycophenolate mofetil and/or corticosteroid treatment on outcomes of belimumab treatment in SLE

THU0271 Favorable Clinical Response to Belimumab at Three Months

Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine

AB0615 Favorable response to belimumab seen at three months

What’s in a name?

What’s in a name?

What's in a name?

Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort

What's in a name?

BASELINE LABORATORY CHARACTERISTICS FROM THE COMBINED PLACEBO GROUPS IN THE BLISS TRIALS ARE PREDICTIVE OF SEVERE FLARE AT 24 WEEKS

PREDICTORS FOR SLE FLARES: BASELINE DISEASE ACTIVITY AND DEMOGRAPHIC CHARACTERISTICS FROM THE BLISS TRIALS' COMBINED PLACEBO GROUPS

What's in a name?

What's in a name?

FAVORABLE CLINICAL RESPONSE TO BELIMUMAB AT THREE MONTHS

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal

Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares

Aktive Filter

Suchergebnisse filtern